<DOC>
	<DOCNO>NCT00948324</DOCNO>
	<brief_summary>The purpose study investigate evaluate effect different intervention ( 1.continuous subcutaneous insulin infusion,2.continuous subcutaneous insulin infusion combine rosiglitazone 3.continuous subcutaneous insulin infusion combine metformin,4.continuous subcutaneous insulin infusion combine α- thioctic acid daily injection , ) glycemic control , B-cell function remission rate newly-diagnosed type 2 diabetic patient .</brief_summary>
	<brief_title>Effect Intensive Therapy Associated With CSII β-cell Function With Newly Diagnosed Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>newly diagnose type 2 diabetes , receive previous antihyperglycaemic therapy</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>ype 2 diabetes mellitus , continuous subcutaneous insulin infusion ,</keyword>
	<keyword>α-lipoic acid , rosiglitazone , metformin，therapy</keyword>
</DOC>